Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Given Consensus Recommendation of “Hold” by Analysts

Shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPTGet Rating) have earned an average recommendation of “Hold” from the seventeen analysts that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $28.07.

Several equities analysts have recently issued reports on the company. StockNews.com assumed coverage on Intercept Pharmaceuticals in a research report on Thursday, March 31st. They set a “buy” rating for the company. B. Riley upgraded Intercept Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $25.00 to $30.00 in a research report on Monday, January 10th. Zacks Investment Research upgraded Intercept Pharmaceuticals from a “sell” rating to a “hold” rating and set a $14.00 target price for the company in a research report on Monday, March 7th. Canaccord Genuity Group cut their target price on Intercept Pharmaceuticals from $31.00 to $29.00 and set a “hold” rating for the company in a research report on Tuesday, March 8th. Finally, Needham & Company LLC cut their target price on Intercept Pharmaceuticals from $30.00 to $25.00 and set a “buy” rating for the company in a research report on Thursday, March 3rd.

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Adage Capital Partners GP L.L.C. acquired a new stake in Intercept Pharmaceuticals during the 4th quarter valued at $20,086,000. Point72 Asset Management L.P. acquired a new stake in Intercept Pharmaceuticals during the 3rd quarter valued at $10,376,000. Millennium Management LLC acquired a new stake in Intercept Pharmaceuticals during the 4th quarter valued at $9,117,000. Geode Capital Management LLC raised its stake in Intercept Pharmaceuticals by 1.8% during the 3rd quarter. Geode Capital Management LLC now owns 497,636 shares of the biopharmaceutical company’s stock valued at $7,389,000 after purchasing an additional 8,971 shares during the period. Finally, Two Sigma Investments LP raised its stake in Intercept Pharmaceuticals by 2.0% during the 3rd quarter. Two Sigma Investments LP now owns 451,218 shares of the biopharmaceutical company’s stock valued at $6,701,000 after purchasing an additional 8,973 shares during the period. 83.44% of the stock is currently owned by institutional investors.

NASDAQ:ICPT opened at $19.27 on Monday. The stock has a 50 day moving average of $16.23 and a 200-day moving average of $16.42. The firm has a market capitalization of $572.57 million, a PE ratio of -8.56 and a beta of 1.27. Intercept Pharmaceuticals has a 52 week low of $11.60 and a 52 week high of $22.36.

Intercept Pharmaceuticals (NASDAQ:ICPTGet Rating) last issued its quarterly earnings data on Wednesday, March 2nd. The biopharmaceutical company reported ($1.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $0.03. The business had revenue of $92.40 million for the quarter, compared to analyst estimates of $91.89 million. During the same quarter in the prior year, the firm posted ($1.58) earnings per share. On average, sell-side analysts forecast that Intercept Pharmaceuticals will post -2.35 EPS for the current fiscal year.

About Intercept Pharmaceuticals (Get Rating)

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults.

See Also

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.